EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of Staphylococcal osteoarticular Infections?

Pier Giorgio Cojutti iD, Sara Tedeschi iD, Eleonora Zamparini, Giacomo Fornaro iD, Manuel Zagarrigo iD, Massimiliano De Paolis iD, Pierluigi Viale, Federico Pea iD

Antibiotics · 01.02.2025 · 14 (2) · 139

DOI: 10.3390/antibiotics14020139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibiotics, online erschienen am 01.02.2025. Verfasst von Pier Giorgio Cojutti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Daptomycin plus fosfomycin combination therapy is a valuable strategy for treating staphylococcal osteoarticular infections (OIs), but hypernatremia and hypokalemia due to sodium overload are important issues. The aim of this study was to assess the likelihood of attaining a pharmacokinetic/pharmacodynamic (PK/PD) target of AUC/MIC > 66.6 and/or of 70%t > MIC with continuous infusion (CI) fosfomycin at the recommended vs. reduced dose in patients with OIs receiving combination therapy with high-dose daptomycin. Adverse events were also evaluated.

Methods

Patients with OIs treated with 8–10 mg/kg daily daptomycin plus CI fosfomycin, and who had a ≥1 TDM assessment of CI fosfomycin, were retrospectively included in the high-dose (16 g daily) or reduced-dose ( MIC and AUC/MIC > 66.6 up to an MIC of 32 mg/L was calculated. A CART analysis was used to identify a cut-off of fosfomycin AUC that indicated occurrence of hypernatremia and/or hypokalemia.

Results

A total of 44 and 39 patients were included in the high- and reduced-dose groups, respectively. The two groups did not differ in terms of demographic characteristics, underlying infectious diseases and microbiological isolates. No differences between groups in attaining both PK/PD targets up to an MIC of 32 mg/L and in C-reactive protein reduction at the end of treatment were observed. Fosfomycin AUC > 8245 mg × h/L and >8326 mg × h/L were associated with hypernatremia and hypokalemia, respectively.

Conclusions

CI fosfomycin at 8 g daily may reach optimal PK/PD target attainment with better safety than the recommended 16 g daily dose in patients with preserved renal function. Targeting fosfomycin AUC at 2131–8326 mg × h/L or steady-state concentration at 88.8–347 mg/L may be adequate for optimizing drug pharmacodynamics up to an MIC of 32 mg/L and minimizing the risk of hypernatremia and hypokalemia.

Schlagwörter

Stichwörter der Autor:innen

PK/PD target attainmentcontinuous infusionfosfomycinhypernatremiahypokalemiatherapeutic drug monitoring

Autor:innen und Institutionen

  • Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy.
  • Clinical Pharmacology Unit, Department of Integrated Infectious Risk Management, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
  • Infectious Diseases Unit, Department of Integrated Infectious Risk Management, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologn, Italy.
  • Orthopaedics and Traumatology Unit, Department of Integrated Infectious Risk Management, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.

ORCID-Profile: Pier Giorgio Cojutti, Sara Tedeschi, Giacomo Fornaro, Manuel Zagarrigo, Massimiliano De Paolis, Federico Pea

Zitieren

APA

Cojutti, P. G., Tedeschi, S., Zamparini, E., Fornaro, G., Zagarrigo, M., De Paolis, M., Viale, P., & Pea, F. (2025). Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of Staphylococcal osteoarticular Infections?. Antibiotics, 14(2), 139. https://doi.org/10.3390/antibiotics14020139

Vancouver

Cojutti PG, Tedeschi S, Zamparini E, Fornaro G, Zagarrigo M, De Paolis M, et al. Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of Staphylococcal osteoarticular Infections?. Antibiotics. 2025;14(2):139. doi:10.3390/antibiotics14020139

BibTeX
@article{Cojutti2025,
  author = {Cojutti, Pier Giorgio and Tedeschi, Sara and Zamparini, Eleonora and Fornaro, Giacomo and Zagarrigo, Manuel and De Paolis, Massimiliano and Viale, Pierluigi and Pea, Federico},
  title = {Could a Reduced Dose of 8 g of Continuous Infusion Fosfomycin Be Considered as Effective as and Safer than a Standard 16 g Dose When Combined with High-Dose Daptomycin in the Treatment of Staphylococcal osteoarticular Infections?},
  journal = {Antibiotics},
  year = {2025},
  volume = {14},
  number = {2},
  pages = {139},
  doi = {10.3390/antibiotics14020139}
}
Kostenlos starten →